6533b835fe1ef96bd129ebb5

RESEARCH PRODUCT

Valpromide is a poor inhibitor of the cytosolic epoxide hydrolase

Franz OeschHelmut ThomasAnders RaneLucio GiulianiG. M. PacificiA. Temellini

subject

Valpromidemedicine.medical_specialtyHealth Toxicology and Mutagenesismedicine.medical_treatmentSodiumchemistry.chemical_elementIn Vitro TechniquesBiologyToxicologyCytosolFetusPregnancyInternal medicineStilbenesmedicineHumansEpoxide hydrolaseEpoxide HydrolasesKidneyValproic AcidGeneral MedicineCytosolAnticonvulsantEndocrinologymedicine.anatomical_structureLiverchemistryEnzyme inhibitorToxicitybiology.proteinAnticonvulsantsFemalemedicine.drug

description

The effect of the antiepileptics valpromide and sodium valproate on the cytosolic epoxide hydrolase was studied in human fetal liver, kidneys and adrenals and from human adult liver and kidneys. Trans-stilbene oxide was used as substrate. Valpromide (10 mM) lowered the activity of the epoxide hydrolase to one half of the control in all organs studied. Sodium valproate (10 mM) was less powerful as an inhibitor than valpromide; however, it exerted a significant inhibition in all tissues studied.

https://doi.org/10.1007/bf00316440